Publication
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerOvarian Carcinomacivic_curation1.00
- drugNiraparibcivic_curation1.00
- geneBRCA1civic_curation1.00
- geneBRCA2civic_curation1.00
- variantBRCA1 Mutationcivic_curation1.00
- variantBRCA2 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 27717299
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRCA1 Mutation + BRCA2 MutationBRCA2BRCA13 | ||||||||
| Niraparib | Fallopian Tube Carcinoma | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11305In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC | civic |
| 〃 | Ovarian CarcinomaALIAS | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID11243In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC | civic |
| 〃 | Peritoneal CarcinomaUNRESOLVED | Predictive | A | Supports Sensitivity Response | 4 | submitted | EID11304In a randomized, double-blind, phase 3 trial, 553 patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with predominantly high-grade serous histologic features were enroll… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC | civic |
| BRCA1 Mutation1 | ||||||||
| Niraparib | High Grade Ovarian Serous CarcinomaUNRESOLVED | Predictive | B | Supports Sensitivity Response | 5 | submitted | EID13120ENGOT-OV16/NOVA was a phase 3, placebo-controlled maintenance trial conducted in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer, the majority of whom… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC | civic |
| BRCA2 Mutation1 | ||||||||
| Niraparib | High Grade Ovarian Serous CarcinomaUNRESOLVED | Predictive | B | Supports Sensitivity Response | 5 | submitted | EID13119ENGOT-OV16/NOVA was a phase 3, placebo-controlled maintenance trial conducted in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer, the majority of whom… (full text at CIViC) PMID 27717299 · Mirza et al., 2016 · Open in CIViC | civic |